EditForce realizes the technology of edition of ARN de “U a C”

FukuokaJapan, 20 October 2022 /PRNewswire/ — EditForce, Inc. (en adelante “EditForce”), con sede en FukuokaJapón, ha realizado la primera tecnologia de edición de ARN del mundo que permite cambiar las edición de ARN de “U” a “C”, y ha demonstrated que esta tecnología funciona even en célu humanas en un estudio conjunto con el profesor Takahiro Nakamura, de la Facultad de Agricultura de la Universidad de Kyushu. The study opens the possibility of editing genetic mutations that could not have been the objective with the existing technologies, and it is hoped that it will contribute to the R&D of therapies for diverse genetic diseases. EditForce will improve the security and efficiency of the edition in its development activities to establish innovative technologies for genetic therapy. The study was published in the scientific journal “Communications Biology” on September 15 (September 16 in JST) of 2022.

Logo: enlace

Research resume

The genome that exists in each human cell is formed by four nucleotide bases — A, C, G and T — whose sequence contains the information necessary to constitute a human body. Las cells generate ARN formed by four nucleotide bases -A, C, G and U- from the genomic sequences, and then produce proteins according to the ARN sequences. Sin embargo, los cambios en un solo nucleótido de un genoma o de una sequencia de ARN causan diversas enfermedades. El tratamiento de estas enfermedades requiere una tecnologia de edición de una sola base para repair las mutations del genoma o del ARN y devolver las sequencias a la normalidad.

At present, the technology of editing the genome has developed rapidly, but the development of the technology of editing sequences of ARN is still limited. Especialmente en lo que se referé a la substitution de una sola base, se han estábalo technologies para substitute “C” por “U” y “A” por “G”, pero la substitution de otras bases aún se ha realizado.

The study explained the mechanism of ARN editing in plants to substitute “U” for “C”, based on which EditForce has realized the first ARN editing technology (substitution of bases) in the world that substitutes “U” for ” C”, and the company demonstrated that this technology works in human cells.

Base editing technologies can be applied to the treatment of diseases caused by a single mutation, and the studio’s “U to C” RNA editing technology opens the possibility of editing mutations that could not have been the objective with existing technologies. In addition, the repair of mutations through the edition of ARN without changes in the sequence of the genome will allow EditForce to offer safer treatments to patients. La empresa espera que esta tecnologia establezca una novedosa terapia génica al mejorar la seguridad y la eficacia de la edición en sus actividades de desarrollo.

This work has been supported by the Beca de Investigación para Jóvenes Académicos financed by the Prefecture of Yamanashi.

Información del artículo Ichinose M., Kawabata M., Akaiwa Y., Shimajiri Y., Nakamura I., Tamai T., Nakamura T., Yagi Y. and Gutmann B. “U-to-C RNA editing by synthetic PPR-DYW proteins in bacteria and human culture cells” Commun Biol. 5, 20 Oct. (2022) – .

About EditForce, Inc.EditForce, Inc., a risk company originating in the University of Kyushu that develops a unique technology for editing ADN/ARN

), was created in May 2015 by KISCO Ltd. y el professor Takahiro Nakamura de la Universidad de Kyushu (former president of EditForce and actual asesor científico de la misma) y financiada por empresas y fondos que tienen un historial de investment en ciencias de la vida y biotecnología. EditForce has as its objective the discovery of drugs that apply PPR technology through joint research with universities and private companies. For more information, visit:

https://www.editforce.co.jp/

Pentatricopeptide (PPR) protein platform technology The PPR is a protein discovered in plants that regulates the expression of genes united to ADN and al ARN de forma specifica a la sequence. PPR proteins are also found in human beings and yeasts, and they have similar functions. El professor Takahiro Nakamuray el Dr.

Yusuke Yagi

, CTO de EditForce, focused on PPR proteins and elucidated the mechanism that determines the specificity of the sequence, and established a technology to create several PPR proteins, each of which has a DNA or RNA sequence specific. Además, es posible manipular y modificar el genoma y el ARN diana tanto dentro como fuera de la célula mediate la fusión con proteins efectoras.View original content: enlace

Leave a Comment

Your email address will not be published. Required fields are marked *